ASH 2019 | FLAG-IDA and ponatinib in blast phase CML: MATCHPOINT trial
Mhairi Copland, PhD, MBChB, FRCP, FRCPath, Paul O’Gorman Leukaemia Research Centre, University of Glasgow, Glasgow, UK, discusses the results from the MATCHPOINT phase I/II trial. This study was designed to find a safe and effective dose of ponatinib when used in combination with FLAG-IDA chemotherapy (fludarabine, cytarabine, idarubicin and G-CSF) in patients with chronic myeloid leukemia (CML) whose disease has moved in to blast phase. Results confirm that FLAG-IDA plus ponatinib is a tolerable combination and represents a potentially important advance in the treatment of blast phase CML, a rare complication which currently has a very poor outcome. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
Get great new content delivered to your inboxSign up